<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00126724</url>
  </required_header>
  <id_info>
    <org_study_id>13G01</org_study_id>
    <secondary_id>NIH Protocol Number: 0504-705</secondary_id>
    <nct_id>NCT00126724</nct_id>
  </id_info>
  <brief_title>Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects</brief_title>
  <official_title>A Phase I/II Study of Repeat Intra-articular Administration of tgAAC94, a Recombinant Adeno-Associated Vector Containing the TNFR:Fc Fusion Gene, in Inflammatory Arthritis Subjects With and Without Concurrent TNF-alpha Antagonists</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Targeted Genetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Targeted Genetics Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The 13G01 clinical trial is a Phase I/II dose escalation study designed to be conducted in&#xD;
      adults with inflammatory arthritis who have persistent moderate or severe swelling in one or&#xD;
      more joints, without a disease severe enough to warrant a change in regimen for the next&#xD;
      three months.&#xD;
&#xD;
      The study will permit subjects who are concurrently on anti-tumor necrosis factor (TNF)-alpha&#xD;
      antagonists. For subjects on disease modifying antirheumatic drugs (DMARDs), a stable regimen&#xD;
      for inflammatory arthritis for the previous three months, with no changes in doses in the&#xD;
      four weeks prior to screening will be required.&#xD;
&#xD;
      The primary objectives are:&#xD;
&#xD;
        1. to evaluate the safety of intra-articular administration of tgAAC94 in subjects&#xD;
           currently taking TNF-alpha antagonists, and&#xD;
&#xD;
        2. to evaluate the safety of repeat intra-articular administration of tgAAC94 (gene therapy&#xD;
           vector).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      tgAAC94 is a recombinant adeno-associated virus serotype 2 (AAV2) vector genetically&#xD;
      engineered to contain the cDNA for a human tumor necrosis factor receptor&#xD;
      (TNFR)-immunoglobulin (IgG1) Fc fusion (TNFR:Fc) gene. The DNA sequence of TNFR:Fc in tgAAC94&#xD;
      codes for a protein sequence identical to etanercept (Enbrel®). TNF-alpha has been strongly&#xD;
      implicated as a major participant in the inflammatory cascade that leads to joint damage and&#xD;
      destruction in diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and&#xD;
      ankylosing spondylitis (AS).&#xD;
&#xD;
      Intra-articular delivery of the TNFR:Fc gene (tgAAC94) should result in expression of the&#xD;
      secreted protein in the joint space and provide local high concentrations of soluble TNFR:Fc&#xD;
      for an extended period of time without requiring frequent administration. Thus, this proposed&#xD;
      therapy would be useful in those inflammatory arthritis patients who have a persistently&#xD;
      problematic joint despite the use of systemic TNF-alpha blockade or who have a limited number&#xD;
      of arthritic joints.&#xD;
&#xD;
      Extensive preclinical studies using rAAV2 containing several different transgenes in a&#xD;
      variety of animal models have shown efficient and persistent gene transfer and expression&#xD;
      with minimal toxicity. The parent virus (wild-type AAV2) is a naturally occurring,&#xD;
      non-replicating virus that depends on a helper virus, such as adenovirus, for replication.&#xD;
      The recombinant AAV2 vector is unable to replicate in target host cells because it lacks the&#xD;
      AAV genes, whose protein products are also required in trans, for replication and packaging&#xD;
      of progeny virus. Extensive epidemiological studies have found AAV2 to be non-pathogenic.&#xD;
&#xD;
      Although there is no cure for arthritis, treatment has been revolutionized by the advent of&#xD;
      anti-TNF-alpha therapies. These include etanercept (Enbrel®), infliximab (Remicade®) and&#xD;
      adalimumab (Humira®), which consist of soluble TNF receptors, chimeric human-mouse&#xD;
      anti-TNF-alpha monoclonal antibodies and fully human anti-TNF-alpha monoclonal antibodies,&#xD;
      respectively. Clinical studies have shown these products to improve the signs and symptoms,&#xD;
      inhibit the structural damage, and impact functional outcomes in patients with these&#xD;
      inflammatory arthritides.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>From time of study drug administration through final study visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe or very severe adverse events</measure>
    <time_frame>From time of study drug administration through final study visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study-drug related adverse events</measure>
    <time_frame>From time of study drug administration through final study visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in tenderness and swelling of target joint</measure>
    <time_frame>All scheduled study visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to qualifying for second injection of study drug</measure>
    <time_frame>Week A12 or 18 or 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in disease activity, as measured by American College of Rheumatology (ACR) criteria, Disease Activity Score (DAS) or Assessments in Ankylosing Spondylitis (ASAS) criteria, as applicable</measure>
    <time_frame>Day A0, Weeks A4, 8, 12, 18, 24, Day B0, Weeks B4, B8, B12, B18, B24, B30, withdrawal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human tumor necrosis factor receptor (TNFR)-immunoglobulin (IgG1) Fc fusion (TNFR:Fc) protein levels in synovial fluid and serum</measure>
    <time_frame>Serum: Days A0,7,Weeks A4,12,24, Days B0,7,Weeks 8,12,18,24,30, withdrawal. Synovium: Days A0,4,Weeks A12,24, Day B0,Weeks 4,12,24, withdrawal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum anti-adeno-associated virus serotype 2 (AAV2) capsid neutralizing antibodies</measure>
    <time_frame>Day A0, Weeks A4, 12, 24, Day B0, Weeks B4, 12,24, 30, withdrawal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Joint inflammation and damage on MRI scan</measure>
    <time_frame>Day A0, Weeks A4, 12, 24</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <condition>Arthritis, Psoriatic</condition>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1x10^11 DRP/mL tgAAC94</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1x10^12 DRP/mL tgAAC94</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1x10^13 DRP/mL tgAAC94</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>tgAAC94 gene therapy vector</intervention_name>
    <description>Single Dose 1x10^11 DRP/mL</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>tgAAC94 gene therapy vector</intervention_name>
    <description>Second dose of 1x10^11 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>tgAAC94 placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>tgAAC94 gene therapy vector</intervention_name>
    <description>Single Dose 1x10^12 DRP/mL tgAAC94</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>tgAAC94 gene therapy vector</intervention_name>
    <description>Second dose of 1x10^12 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>tgAAC94 gene therapy vector</intervention_name>
    <description>Single Dose 1x10^13 DRP/mL tgAAC94</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>tgAAC94 gene therapy vector</intervention_name>
    <description>Second dose of 1x10^13 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS)&#xD;
             diagnosed according to established criteria.&#xD;
&#xD;
          -  Persistent moderate (grade 2) or severe (grade 3) swelling due to inflammatory&#xD;
             arthritis in at least one peripheral joint eligible for injection.&#xD;
&#xD;
          -  For subjects with RA, an adequate trial of at least one disease-modifying drug (DMARD)&#xD;
             prior to screening.&#xD;
&#xD;
          -  For subjects currently on DMARD(s), a stable regimen of inflammatory arthritis for the&#xD;
             previous three months, with no changes in doses four weeks prior to screening.&#xD;
&#xD;
          -  Age greater than 18 years and less than 75 years at the time of screening.&#xD;
&#xD;
          -  Willingness to practice effective birth control measures during the study (through&#xD;
             week 36), if male or female of reproductive ability.&#xD;
&#xD;
          -  Able to give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disease severe enough to warrant a change in regimen for inflammatory arthritis in the&#xD;
             next three months.&#xD;
&#xD;
          -  Discontinuation of etanercept in the past because of safety concerns.&#xD;
&#xD;
          -  Current use of anakinra (Kineret®)or abatacept (Orencia®).&#xD;
&#xD;
          -  Corticosteroid therapy at doses higher than the equivalent of 10 mg prednisone per&#xD;
             day.&#xD;
&#xD;
          -  Steroid or hyaluronate injection in the target joint or receipt of an investigational&#xD;
             agent less than four weeks prior to screening.&#xD;
&#xD;
          -  Class IV ACR functional status (Hochberg et al., 1992).&#xD;
&#xD;
          -  Any of the following laboratory values: Hemoglobin &lt;8.5 gm/dL, white blood cell count&#xD;
             &lt;3500 per mm cube, platelet &lt;100 K/uL, creatinine &gt;2 mg/dL, bilirubin &gt;2 mg/dL, AST or&#xD;
             ALT &gt;2 times the upper limit of normal, or abnormal coagulation profiles (&gt;2 seconds&#xD;
             beyond upper range of normal PT or PTT).&#xD;
&#xD;
          -  Known HIV infection, known hepatitis C infection, or known positive serologic test for&#xD;
             hepatitis B surface antigen.&#xD;
&#xD;
          -  Positive PPD, unless previously treated with appropriate prophylaxis.&#xD;
&#xD;
          -  Pregnancy or lactation, either at the time of screening or planned in the next 18&#xD;
             months.&#xD;
&#xD;
          -  Inflammatory bowel disease, such as Crohn's disease or ulcerative colitis.&#xD;
&#xD;
          -  Serious medical disease, such as severe liver or kidney disease, uncompensated&#xD;
             congestive heart failure, myocardial infarction within six months, unstable angina,&#xD;
             uncontrolled hypertension, severe pulmonary disease or uncontrolled asthma,&#xD;
             demyelinating neurological disease, history of cancer (other than cutaneous basal and&#xD;
             squamous cell carcinoma) with less than five years documentation of a disease-free&#xD;
             state, insulin-dependent diabetes, recurrent opportunistic infections or other&#xD;
             concurrent medical condition that, in the opinion of the investigator, would make the&#xD;
             subject unsuitable for the study.&#xD;
&#xD;
          -  Unlikely to comply with protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison Heald, MD</last_name>
    <role>Study Director</role>
    <affiliation>Targeted Genetics Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Valley Arthritis Center</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catalina Pointe Clinical Research, Inc</name>
      <address>
        <city>Tuscon</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Medical Advances</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boling Clinical Trials</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Arthritis Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RASF-Clinical Research Center</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocala Rheumatology Research Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Stuart</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34996</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coeur d'Alene Arthritis Clinic</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Center for Clinical Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Osteoporosis Center of Maryland</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Center of Reno</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Medical Associates</name>
      <address>
        <city>Johnson City</city>
        <state>New York</state>
        <zip>13790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bone and Joint Hospital Research Dept.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatic Disease Associates</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Rheumatology Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Consultation Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research San Antonio Northeast</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Rheumatology Associates, PLLC</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.targetedgenetics.com</url>
    <description>Sponsor Home Page</description>
  </link>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>August 2, 2005</study_first_submitted>
  <study_first_submitted_qc>August 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2005</study_first_posted>
  <last_update_submitted>July 27, 2009</last_update_submitted>
  <last_update_submitted_qc>July 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Rae Saltzstein</name_title>
    <organization>Targeted Genetics Corporation</organization>
  </responsible_party>
  <keyword>tgAAC94</keyword>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Inflammatory arthritis</keyword>
  <keyword>Arthritis</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>AAV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

